Lancet Oncology

Papers
(The H4-Index of Lancet Oncology is 99. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Health insurance system in Japan faces risk of politicisation930
Navigating the complexity: reflections on the development of perioperative cancer treatments690
Dual therapy in metastatic castration-resistant prostate cancer615
US FDA proposes stronger laboratory test oversight587
Enhancing equity and long-term impact assessments in radiotherapy environmental studies521
Toxicity assessment bias in the PACE-C trial – Authors' reply461
New national cancer registry for France457
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX434
The future of precise cancer chronotherapeutics407
Palliative radiotherapy for hepatic cancer pain379
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply359
SANO trial: innovations, risks, and unanswered questions353
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia352
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer348
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t335
Antibody–drug conjugates in acute myeloid leukaemia: more research needed319
Olanzapine for chemotherapy-induced nausea and vomiting control308
Study bolsters concerns about US FDA accelerated drug approvals307
Survivorship after neoadjuvant chemotherapy270
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply259
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy253
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer250
Combination immunotherapy in chemotherapy in gastric cancer249
Correction to Lancet Oncol 2022; 23: 1124–26248
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC245
Use of artificial intelligence to enhance detection of nodal metastases245
Patients with cancer in Louisiana denied fertility preservation cover231
A new generation of comprehensive precision oncology trials228
The GLOW trial in chronic lymphocytic leukaemia225
Medical treatment for active breast cancer brain metastases224
Precision medicine for children with cancer220
Concern for cancer drugs in USA–EU tariff war217
Myung-Ju Ahn: battling sexism in medicine and supporting the next generation216
IVLBCL mimicking VEXAS syndrome215
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges214
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX – Authors' reply213
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial204
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies202
Determining the optimal use of approved drugs in oncology201
Italy to pass law on the right to be forgotten for cancer survivors197
Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB–C and III cutaneous malignant melanoma (TRIM): an interim analysis o195
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries190
The silent malignant mesothelioma epidemic: a call to action186
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas185
Correction to Lancet Oncol 2021; 22: 1081–92184
US Surgeon General calls for cancer warning labels on alcohol181
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study179
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis176
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, 176
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult175
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial173
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi173
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, 172
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial172
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial170
Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus160
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study159
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm158
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 157
Innovation in gynaecological cancer: highlighting global disparities155
Focus where it matters: turning insights into advocacy154
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer153
Syrian cancer patients regain treatment access in Türkiye147
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-repo147
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update147
Mantle cell lymphoma: is it time for risk-adapted treatment?145
Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer–Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa:143
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospecti143
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study142
Challenges and prospects for cancer treatment in prison settings140
Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK139
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire134
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial132
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial131
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer131
De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer130
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study128
Cancer on the agenda during IAEA Director General's visit to Chile127
Balancing clinical benefit and social value: challenges in HTA assessments125
Lung cancer rates highest among British Bangladeshi men125
Correction to Lancet Oncol 2023; 24: e242122
Radiotherapy and conflict: from disruption to expansion and hope121
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations115
Clearing the radiotherapy backlog: innovation to pave the way114
A biobank perspective on use of tissue samples donated by trial participants112
2022 ASTRO annual meeting112
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer112
Common Sense Oncology: including everyone112
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?111
Decentralised, point-of-care CAR-T for multiple myeloma109
Correction to Lancet Oncol 2020; 21: 699–709108
Effect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study107
Importance of clinical research for the UK's 10-year cancer plan107
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer107
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA107
Essential anticancer medicines for children: defining what matters most for Europe104
Oral contraceptives and risk of liver cancer103
WHO reports health service disruptions due to suspensions of aid102
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit100
Systemic therapy for brain metastases: a changing landscape99
0.16176104545593